8-Hydroxy-2′-deoxyguanosine (8-OHdG) as a possible marker of arsenic poisoning: a clinical case study on the relationship between concentrations of 8-OHdG and each arsenic compound in urine of an acute promyelocytic leukemia patient being treated with arsenic trioxide

[1]  Gun-Hee Kim,et al.  Biomarkers for oxidative stress status of DNA, lipids, and proteins in vitro and in vivo cancer research. , 2007, Toxicology.

[2]  木村 慎吾.  Evaluation of Urinary 8-Hydroxydeoxyguanine in Healthy Japanese People , 2007 .

[3]  K. Kinoshita,et al.  Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. , 2006, Biological & pharmaceutical bulletin.

[4]  T. Naoe,et al.  Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy. , 2006, Haematologica.

[5]  S. Hirata,et al.  Determination of arsenic species and arsenosugars in marine samples by HPLC–ICP–MS , 2005, Analytical and bioanalytical chemistry.

[6]  M. Tallman,et al.  Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Pi,et al.  Evaluation of DNA damage in patients with arsenic poisoning: urinary 8-hydroxydeoxyguanine. , 2004, Toxicology and applied pharmacology.

[8]  C. Dang,et al.  Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  X. Le,et al.  Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. , 2004, Chemical research in toxicology.

[10]  本多 幸.  Correlation of urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG), a biomarker of oxidative DNA damage, and clinical features of hematological disorders : A pilot study , 2003 .

[11]  T. Naoe,et al.  In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. , 1996, Blood.

[12]  M. Vahter.  Species differences in the metabolism of arsenic compounds , 1994 .

[13]  M. Vahter.  What are the chemical forms of arsenic in urine, and what can they tell us about exposure? , 1994, Clinical chemistry.

[14]  P. McPhie.  Analytical techniques for heavy metals in biological fluids: Edited by S. Facchetti, Elsevier, Amsterdam/Oxford/New York, 1982. 288 pp , 1984 .

[15]  H. Roels,et al.  Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers , 1981, International archives of occupational and environmental health.

[16]  R. Braman.  Arsenic in the environment , 1975 .